vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Madison Square Garden Entertainment Corp. (MSGE). Click either name above to swap in a different company.

Madison Square Garden Entertainment Corp. is the larger business by last-quarter revenue ($424.8M vs $321.1M, roughly 1.3× MADRIGAL PHARMACEUTICALS, INC.). Madison Square Garden Entertainment Corp. runs the higher net margin — 21.8% vs -18.2%, a 40.1% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 12.5%).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

MDGL vs MSGE — Head-to-Head

Bigger by revenue
MSGE
MSGE
1.3× larger
MSGE
$424.8M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+198.3% gap
MDGL
210.8%
12.5%
MSGE
Higher net margin
MSGE
MSGE
40.1% more per $
MSGE
21.8%
-18.2%
MDGL

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
MDGL
MDGL
MSGE
MSGE
Revenue
$321.1M
$424.8M
Net Profit
$-58.6M
$92.7M
Gross Margin
Operating Margin
-18.6%
38.6%
Net Margin
-18.2%
21.8%
Revenue YoY
210.8%
12.5%
Net Profit YoY
1.4%
22.2%
EPS (diluted)
$-2.55
$1.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
MSGE
MSGE
Q4 25
$321.1M
$424.8M
Q3 25
$287.3M
$154.1M
Q2 25
$212.8M
$145.1M
Q1 25
$137.3M
$206.0M
Q4 24
$103.3M
$377.6M
Q3 24
$62.2M
$134.1M
Q2 24
$177.6M
Q1 24
$0
$191.6M
Net Profit
MDGL
MDGL
MSGE
MSGE
Q4 25
$-58.6M
$92.7M
Q3 25
$-114.2M
$-21.7M
Q2 25
$-42.3M
$-27.2M
Q1 25
$-73.2M
$8.0M
Q4 24
$-59.4M
$75.9M
Q3 24
$-107.0M
$-19.3M
Q2 24
$66.9M
Q1 24
$-147.5M
$2.8M
Gross Margin
MDGL
MDGL
MSGE
MSGE
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
MDGL
MDGL
MSGE
MSGE
Q4 25
-18.6%
38.6%
Q3 25
-39.7%
-19.3%
Q2 25
-22.2%
-17.7%
Q1 25
-57.8%
13.3%
Q4 24
-64.8%
36.8%
Q3 24
-187.1%
-13.8%
Q2 24
-5.0%
Q1 24
8.8%
Net Margin
MDGL
MDGL
MSGE
MSGE
Q4 25
-18.2%
21.8%
Q3 25
-39.8%
-14.0%
Q2 25
-19.9%
-18.7%
Q1 25
-53.4%
3.9%
Q4 24
-57.5%
20.1%
Q3 24
-172.0%
-14.4%
Q2 24
37.7%
Q1 24
1.5%
EPS (diluted)
MDGL
MDGL
MSGE
MSGE
Q4 25
$-2.55
$1.94
Q3 25
$-5.08
$-0.46
Q2 25
$-1.90
$-0.56
Q1 25
$-3.32
$0.17
Q4 24
$-2.50
$1.56
Q3 24
$-4.92
$-0.40
Q2 24
$1.32
Q1 24
$-7.38
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
MSGE
MSGE
Cash + ST InvestmentsLiquidity on hand
$198.7M
$157.1M
Total DebtLower is stronger
$339.9M
$554.6M
Stockholders' EquityBook value
$602.7M
$36.0M
Total Assets
$1.3B
$1.8B
Debt / EquityLower = less leverage
0.56×
15.40×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
MSGE
MSGE
Q4 25
$198.7M
$157.1M
Q3 25
$295.7M
$29.9M
Q2 25
$186.2M
$43.0M
Q1 25
$183.6M
$89.0M
Q4 24
$100.0M
$54.9M
Q3 24
$232.7M
$37.3M
Q2 24
$33.3M
Q1 24
$622.5M
$28.0M
Total Debt
MDGL
MDGL
MSGE
MSGE
Q4 25
$339.9M
$554.6M
Q3 25
$339.8M
$581.7M
Q2 25
$118.4M
$568.8M
Q1 25
$118.0M
$577.4M
Q4 24
$117.6M
$584.7M
Q3 24
$117.1M
$647.0M
Q2 24
$599.2M
Q1 24
$116.1M
$602.5M
Stockholders' Equity
MDGL
MDGL
MSGE
MSGE
Q4 25
$602.7M
$36.0M
Q3 25
$625.7M
$-65.8M
Q2 25
$696.0M
$-13.3M
Q1 25
$710.6M
$9.5M
Q4 24
$754.4M
$10.3M
Q3 24
$777.2M
$-48.7M
Q2 24
$-23.2M
Q1 24
$850.8M
$-94.6M
Total Assets
MDGL
MDGL
MSGE
MSGE
Q4 25
$1.3B
$1.8B
Q3 25
$1.4B
$1.7B
Q2 25
$1.0B
$1.7B
Q1 25
$996.6M
$1.7B
Q4 24
$1.0B
$1.6B
Q3 24
$1.1B
$1.6B
Q2 24
$1.6B
Q1 24
$1.1B
$1.5B
Debt / Equity
MDGL
MDGL
MSGE
MSGE
Q4 25
0.56×
15.40×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
60.61×
Q4 24
0.16×
56.61×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
MSGE
MSGE
Operating Cash FlowLast quarter
$-133.5M
$164.4M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.77×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
MSGE
MSGE
Q4 25
$-133.5M
$164.4M
Q3 25
$79.8M
$19.8M
Q2 25
$-47.1M
$-27.0M
Q1 25
$-88.9M
$56.8M
Q4 24
$-104.5M
$112.9M
Q3 24
$-67.0M
$-27.4M
Q2 24
$212.0K
Q1 24
$-149.2M
$5.8M
Free Cash Flow
MDGL
MDGL
MSGE
MSGE
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
Q1 24
$-149.5M
FCF Margin
MDGL
MDGL
MSGE
MSGE
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Q1 24
Capex Intensity
MDGL
MDGL
MSGE
MSGE
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Q1 24
Cash Conversion
MDGL
MDGL
MSGE
MSGE
Q4 25
1.77×
Q3 25
Q2 25
Q1 25
7.07×
Q4 24
1.49×
Q3 24
Q2 24
0.00×
Q1 24
2.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

MSGE
MSGE

Ticketing And Venue License Fee Revenues$263.5M62%
Food Beverage And Merchandise Revenues$64.3M15%
Related Party$43.9M10%
Arena Licensing Fees And Other Leasing Revenue$35.2M8%
Other$15.9M4%

Related Comparisons